Home Interviews Aqilion aims for best-in-class with new programme

Aqilion aims for best-in-class with new programme

Aqilion's CEO Sarah Fredriksson

Aqilion aims for best-in-class with new programme

14 May, 2024

Aqilion is in the business of discovering and developing new drug targets that could reduce the burden of chronic inflammatory illnesses. The company has three ongoing pipeline projects, and a fourth programme has just been announced with PKCtheta as the target. Aqilion’s CEO Sarah Fredriksson joined us in the studio to tell us all about it!

See the interview with Aqilion’s CEO Sarah Fredriksson below.

YouTube video

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev